Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Fahriye Tugba Kos"'
Publikováno v:
Journal of the College of Physicians and Surgeons Pakistan. 31:1428-1432
OBJECTIVE To determine the PNI's prognostic effect of prognostic nutritional index (PNI) on operated papilla vateri tumor (PVT) survival. STUDY DESIGN Descriptive study. PLACE AND DURATION OF STUDY Department of Medical Oncology, Ankara City Hospital
Autor:
Mutlu Dogan, Servet Guresci, Onder Bozdogan, Oznur Bal, Yusuf Acikgoz, Yakup Ergun, Fahriye Tugba Kos
Publikováno v:
Expert Review of Molecular Diagnostics. 20:851-859
We aimed to evaluate the correlation between MKK4 expression and clinicopathological features, KRAS/NRAS mutation in colorectal cancer. MKK4 expression was assessed by immunoreactivity score (IRS)....
Publikováno v:
Journal of Clinical Oncology. 37:e14500-e14500
e14500 Background: We aimed to evaluate correlation between MKK4 exp & clinicopathological features in mCRC Methods: MKK4 exp was assessed by immunoreactive score (IRS). Staining intensity [0 (no), 1+ (weak), 2+ (moderate), 3+ (strong)] & % of positi
Publikováno v:
Journal of Clinical Oncology. 36:e16176-e16176
e16176Background: Grade 1 & 2 gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are well-differentiated (WD). Methods: We evaluated 115 nonfunctional WD GEP-NETs retrospectively. Results: Med...
Autor:
Metin Isik, Dogan Uncu, Hatice Odabas, Mehmet Metin Seker, Fahriye Tugba Kos, Nurullah Zengin
Publikováno v:
Medical oncology (Northwood, London, England). 28(2)
The optimal therapy for carcinoma of unknown primary site (CUPS) is still under investigation. In this retrospective trial, we reported the response rates and overall and progression free survival of 23 CUPS patients that were treated with gemcitabin
Autor:
Burak Civelek, Nuriye Ozdemir, Zafer Arik, Dogan Uncu, Sercan Aksoy, Mehmet Ali Nahit Sendur, Sebnem Yaman, Fahriye Tugba Kos, Nurullah Zengin
Publikováno v:
Journal of Clinical Oncology. 30:e13031-e13031
e13031 Background: The most important dose-limiting manifestation of cisplatin is renal tubular dysfunction and a cumulative impairment in renal function, as manifested by a decline in the glomerular filtration rate (GFR). There is a clinical need to